



19 September 2024

## Trading update

**ALS Limited** (ASX: ALQ) today provides a trading update ahead of the half year ending 30 September 2024 (H1 FY25).

### Commodities

- The business has recently encountered volume headwinds within the Minerals division.
- As communicated at the AGM, volumes in geochemistry and metallurgy (“Minerals”) remain patchy and fluctuations have become even more pronounced in July and August.
- This is especially the case in the Australian and Latin American markets and has resulted in volume declines and margin pressure in these markets.
- North American volumes have been more stable and are holding in line with pcp (H1 FY24).
- While Minerals margins are down on pcp, margins remain resilient at ~30%.

### Life Sciences

- On a more positive note, organic growth in Life Sciences (especially Environmental) has been in line with expectations.
- The integration of the recent acquisitions of Nuvisan, Wessling and York are on track.
- Nuvisan is starting to see some positive medium and long-term improvement in the business development pipeline.
- As previously communicated, these acquisitions will be EPS dilutive in FY25 after taking into account initial trading and all relevant interest costs.

### Corporate and interest costs

- Corporate costs are broadly in line with guidance while interest expense is tracking slightly above due to higher average debt levels and lease interest costs from recent acquisitions.

### Outlook

- The combined impact of the above for the September half is while underlying EBIT is expected to be slightly ahead of pcp, underlying NPAT is expected to be down by ~5%.
- A further update on outlook will be provided with the H1 FY25 results, which will be announced to the ASX on Tuesday 19 November 2024.

Conference call details can be found below.

Authorised for release by the Board of Directors.

### For further information please contact:

#### Michael Williams

Group Treasurer, Investor Relations & Business Integration Director

[michael.williams@alsglobal.com](mailto:michael.williams@alsglobal.com)

M: + 61 409 001 308

#### Investor Relations

[investor@alsglobal.com](mailto:investor@alsglobal.com)

ALS Limited



### About ALS Limited (ASX: ALQ)

ALS is a global leader in testing, providing comprehensive testing solutions to clients in a wide range of industries around the world. Using state-of-the-art technologies and innovative methodologies, our dedicated international teams deliver the highest-quality testing services and personalised solutions supported by local expertise. We help our clients leverage the power of data-driven insights for a safer and healthier world.

### Event details

Malcolm Deane, CEO and Managing Director, and Stuart Hutton, Chief Financial Officer, will be holding a conference call to discuss the trading update and field questions.

Date: 19 September 2024

Time: 10am (AEST)

Participants will need to pre-register for the conference call at the link below. You will then receive an email with the dial in number and a unique code, which is to be input when dialing into the call.

**Register for conference call:** <https://register.vevent.com/register/BI60a5da08932b49a9822d1e017826573e>

-ENDS-

For personal use only